Viking Therapeutics (VKTX) gained overnight ahead of Q1 earnings, with analysts seeing over 170% upside. While losses are expected to widen with zero revenue, focus remains on its Phase 3 Vanquish GLP-1 program. The stock competes with Novo and Lilly, and Wall Street remains bullish despite recent slumps.